Why the study?
Does rivaroxaban prevent recurrence or aggravation of symptomatic VTE in Japanese patients with venous thromboembolism?
Does rivaroxaban prevent recurrence or aggravation of symptomatic VTE in Japanese patients with venous thromboembolism?
In Japanese clinical practice, rivaroxaban demonstrated effectiveness and safety for treating a broad range of VTE patients, with low rates of recurrence and major bleeding.
Answers are grounded in this paper and cite their sources.
Supports low recurrence and bleeding with rivaroxaban in Japanese VTE; leaves open need for randomized confirmation.
BACKGROUND: There is insufficient real-world data on the current status of Japanese patients with venous thromboembolism (VTE) or its treatment and prevention with rivaroxaban. METHODS AND RESULTS: In this multicenter, prospective, observational study conducted in Japan, 1,039 patients with acute symptomatic/asymptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE) with or without DVT prescribed rivaroxaban were enrolled at 152 institutions and observed for a median of 21.3 months. Mean age was 68.0±14.7 years, mean body weight was 60.3±14.1 kg, 59.0% were females, and 19.0% had active cancer. Incidences of recurrence or aggravation of symptomatic VTE (primary effectiveness outcome) and major bleeding (principal safety outcome) were 2.6% and 2.9% per patient-year, respectively. These outcomes did not differ between patients with DVT and those with PE (primary effectiveness outcome: 2.6% vs. 2.5% per patient-year, P=0.810; principal safety outcome: 3.5% vs. 2.4% per patient-year, P=0.394). The incidence of composite clinically relevant events, including recurrence or aggravation of symptomatic VTE, acute coronary syndrome, ischemic stroke, all-cause death, or major bleeding events, was 9.2% per patient-year. Multivariate analysis revealed that male sex, being underweight, having active cancer, chronic heart and lung disease, and previous stroke were independent determinants for composite clinically relevant events. CONCLUSIONS: In Japanese clinical practice, a single-drug approach with rivaroxaban was demonstrated to be a valuable treatment for a broad range of VTE patients.
No takes yet. Share an insight, caveat, or question.
Okumura et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: